FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3014176673> ?p ?o ?g. }

• W3014176673 abstract "Background There is little knowledge about the significance of extremely high values (>655) for the ratio of sF lt‐1 (soluble fms‐like tyrosine kinase 1) to Pl GF (placental growth factor). We aim to describe the time‐to‐delivery interval and maternal and perinatal outcomes when such values are demonstrated while assessing suspected or confirmed placental dysfunction based on clinical or sonographic criteria. Methods and Results A multicenter retrospective cohort study was performed on 237 singleton gestations between 20+0 and 37+0 weeks included at the time of first demonstrating a sF lt‐1/Pl GF ratio >655. Clinicians were aware of this result, but standard protocols were followed for delivery indication. Main outcomes were compared for women with and without preeclampsia at inclusion. In those with preeclampsia (n=185, of whom 77.3% had fetal growth restriction), severe preeclampsia features and fetal growth restriction in stages III or IV were present in 49.2% and 13.5% cases, respectively, at inclusion and in 77.3% and 28.6% cases, respectively, at delivery. In the group without preeclampsia (n=52, 82.7% had fetal growth restriction), these figures were 0% and 30.8%, respectively, at inclusion and 21.2% and 50%, respectively, at delivery. Interestingly, 28% of women without initial preeclampsia developed it later. The median time to delivery was 4 days (interquartile range: 1–6 days) and 7 days (interquartile range: 3–12 days), respectively ( P <0.01). Overall, perinatal mortality was 62.1% before 24 weeks; severe morbidity surpassed 50% before 29 weeks but became absent from 34 weeks. Maternal serious morbidity was high at any gestational age. Conclusions An sF lt‐1/Pl GF ratio >655 is almost invariably associated with preeclampsia or fetal growth restriction that progresses rapidly. In our tertiary care settings, we observed that maternal adverse outcomes were high throughout gestation, whereas perinatal adverse outcomes diminished as pregnancy advanced." @default.
• W3014176673 created "2020-04-10" @default.
• W3014176673 creator A5007687140 @default.
• W3014176673 creator A5012125385 @default.
• W3014176673 creator A5014307465 @default.
• W3014176673 creator A5023465796 @default.
• W3014176673 creator A5034268316 @default.
• W3014176673 creator A5036421024 @default.
• W3014176673 creator A5048080710 @default.
• W3014176673 creator A5072741277 @default.
• W3014176673 creator A5081376727 @default.
• W3014176673 creator A5082138070 @default.
• W3014176673 creator A5087922313 @default.
• W3014176673 creator A5088921346 @default.
• W3014176673 date "2020-04-09" @default.
• W3014176673 modified "2023-10-03" @default.
• W3014176673 title "Maternal and Perinatal Outcomes Associated With Extremely High Values for the sFlt‐1 (Soluble fms‐Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) Ratio" @default.
• W3014176673 cites W1963906907 @default.
• W3014176673 cites W1968532354 @default.
• W3014176673 cites W2039503336 @default.
• W3014176673 cites W2059070269 @default.
• W3014176673 cites W2065594976 @default.
• W3014176673 cites W2093274439 @default.
• W3014176673 cites W2098593821 @default.
• W3014176673 cites W2118452910 @default.
• W3014176673 cites W2124588032 @default.
• W3014176673 cites W2134502189 @default.
• W3014176673 cites W2170867031 @default.
• W3014176673 cites W2233974801 @default.
• W3014176673 cites W2334531770 @default.
• W3014176673 cites W2415044900 @default.
• W3014176673 cites W2519262228 @default.
• W3014176673 cites W2751360904 @default.
• W3014176673 cites W2781893060 @default.
• W3014176673 cites W2810519232 @default.
• W3014176673 cites W2930104874 @default.
• W3014176673 cites W3160565403 @default.
• W3014176673 cites W4233259059 @default.
• W3014176673 cites W4248368453 @default.
• W3014176673 cites W4251118184 @default.
• W3014176673 cites W4382916220 @default.
• W3014176673 doi "https://doi.org/10.1161/jaha.119.015548" @default.
• W3014176673 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7428600" @default.
• W3014176673 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32248765" @default.
• W3014176673 hasPublicationYear "2020" @default.
• W3014176673 type Work @default.
• W3014176673 sameAs 3014176673 @default.
• W3014176673 citedByCount "11" @default.
• W3014176673 countsByYear W30141766732020 @default.
• W3014176673 countsByYear W30141766732021 @default.
• W3014176673 countsByYear W30141766732022 @default.
• W3014176673 countsByYear W30141766732023 @default.
• W3014176673 crossrefType "journal-article" @default.
• W3014176673 hasAuthorship W3014176673A5007687140 @default.
• W3014176673 hasAuthorship W3014176673A5012125385 @default.
• W3014176673 hasAuthorship W3014176673A5014307465 @default.
• W3014176673 hasAuthorship W3014176673A5023465796 @default.
• W3014176673 hasAuthorship W3014176673A5034268316 @default.
• W3014176673 hasAuthorship W3014176673A5036421024 @default.
• W3014176673 hasAuthorship W3014176673A5048080710 @default.
• W3014176673 hasAuthorship W3014176673A5072741277 @default.
• W3014176673 hasAuthorship W3014176673A5081376727 @default.
• W3014176673 hasAuthorship W3014176673A5082138070 @default.
• W3014176673 hasAuthorship W3014176673A5087922313 @default.
• W3014176673 hasAuthorship W3014176673A5088921346 @default.
• W3014176673 hasBestOaLocation W30141766731 @default.
• W3014176673 hasConcept C119060515 @default.
• W3014176673 hasConcept C126322002 @default.
• W3014176673 hasConcept C131872663 @default.
• W3014176673 hasConcept C167135981 @default.
• W3014176673 hasConcept C172680121 @default.
• W3014176673 hasConcept C2776871010 @default.
• W3014176673 hasConcept C2777218350 @default.
• W3014176673 hasConcept C2778780700 @default.
• W3014176673 hasConcept C2779184299 @default.
• W3014176673 hasConcept C2779234561 @default.
• W3014176673 hasConcept C2993726049 @default.
• W3014176673 hasConcept C46973012 @default.
• W3014176673 hasConcept C54355233 @default.
• W3014176673 hasConcept C71924100 @default.
• W3014176673 hasConcept C86803240 @default.
• W3014176673 hasConceptScore W3014176673C119060515 @default.
• W3014176673 hasConceptScore W3014176673C126322002 @default.
• W3014176673 hasConceptScore W3014176673C131872663 @default.
• W3014176673 hasConceptScore W3014176673C167135981 @default.
• W3014176673 hasConceptScore W3014176673C172680121 @default.
• W3014176673 hasConceptScore W3014176673C2776871010 @default.
• W3014176673 hasConceptScore W3014176673C2777218350 @default.
• W3014176673 hasConceptScore W3014176673C2778780700 @default.
• W3014176673 hasConceptScore W3014176673C2779184299 @default.
• W3014176673 hasConceptScore W3014176673C2779234561 @default.
• W3014176673 hasConceptScore W3014176673C2993726049 @default.
• W3014176673 hasConceptScore W3014176673C46973012 @default.
• W3014176673 hasConceptScore W3014176673C54355233 @default.
• W3014176673 hasConceptScore W3014176673C71924100 @default.
• W3014176673 hasConceptScore W3014176673C86803240 @default.
• W3014176673 hasIssue "7" @default.
• W3014176673 hasLocation W30141766731 @default.
• W3014176673 hasLocation W30141766732 @default.
• W3014176673 hasLocation W30141766733 @default.

• next